Adam J. Gadzinksi, MD, MS, on the Impact of Telemedicine on Patient-Reported Outcomes

Video

The study assessed the impact of a rurally focused telemedicine program on patient outcomes in the urologic oncology outpatient clinic at the University of Washington Medical Center.

Findings from a study presented at the Society of Urologic Oncology 21st Annual Meeting revealed the impact of a rurally focused telemedicine program on patient outcomes in the urologic oncology outpatient clinic at the University of Washington Medical Center (UWMC).

The investigators ultimately discovered that telemedicine provides a medium for cancer care delivery that eliminates the significant travel burden associated with in-person clinic appointments.

In an interview with CancerNetwork®, Adam J. Gadzinski, MD, MS, urologic oncology fellow and an acting instructor of Urologic Oncology at the Urology Clinic at UWMC, explained the implications of these study results.

Transcription:

I think for us, what we really took out of this was that patients were spending a lot just to come and see us in clinic. And that telemedicine, in terms of at least the outcomes of patient satisfaction, really was equivalent to in person visits. We had very complex discussions about very challenging cancer issues and decisions that patients had to make. And I think we found that having those discussions over telemedicine was pretty darn similar to in person visits.

And for certain parts of urologic cancer care, physical exam is not always the kind of hinge point of a decision and so you don't have to examine someone when you have their CT scan that you can review with them. You know, maybe they don't need to drive from eastern Washington 5 hours for you to, to you know, lay your hands on their abdomen and then look at the CT scan with them and make all of your cancer treatment decisions based on the CT scan.

There are some patients you do have to kind of see them in person and examine them in person before you decide on treatment decisions. And sometimes what we found is the telemedicine really streamlined their in person visit when they did come, so then when they come they're also getting, you know, a repeat CT scan, they’re getting labs, and so their trip to Washington, to Seattle, was more of a implementing a plan and less kind of discovering what that plan might be.

Recent Videos
Harmonizing protocols across the health care system may bolster the feasibility of giving bispecifics to those with lymphoma in a community setting.
Although accuracy remains a focus in whole-body MRI testing in patients with Li-Fraumeni syndrome, comfortable testing experiences may ease anxiety.
Subsequent testing among patients in a prospective study may affirm the ability of cfDNA sequencing to detect cancers in those with Li-Fraumeni syndrome.
cfDNA sequencing may allow for more accessible, frequent, and sensitive testing compared with standard surveillance in Li-Fraumeni syndrome.
STX-478 showed efficacy in patients with advanced solid tumors regardless of whether they had kinase domain or helical PI3K mutations.
STX-478 may avoid adverse effects associated with prior PI3K inhibitors that lack selectivity for the mutated protein vs the wild-type protein.
Phase 1 data may show the possibility of rationally designing agents that can preferentially target PI3K mutations in solid tumors.
Funding a clinical trial to further assess liquid biopsy in patients with Li-Fraumeni syndrome may help with detecting cancers early across the board.
Michael J. Hall, MD, MS, FASCO, discusses the need to reduce barriers to care for those with Li-Fraumeni syndrome, including those who live in rural areas.
Related Content